Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
A new disclosure tied to Ford has added to investors’ focus on Micron Technology’s longer-range customer commitments and what they could mean for revenue durability, according to a recent Yahoo Finance report.
THE APEX TIMES
THE APEX TIMES
A market note suggests Salesforce’s stock could look cheap if its planned push into Fin resolves the company’s biggest revenue-growth challenge. The company’s public disclosures so far provide limited specifics on how the deal will translate into near-term results.
THE APEX TIMES
The plan centers on demonstrations of programs and partnerships Boeing says support aircraft and defense customers, with details not specified in the initial announcement.
THE APEX TIMES
A Yahoo Finance roundup of Zacks Market Edge named Ford Motor (F) alongside Wayfair and Cisco, highlighting investor attention on autos, online retail and enterprise networking.
THE APEX TIMES
A market drop has coincided with questions about how much of Nike’s recent profit picture was driven by a temporary tariff-related benefit, even as the company’s CEO has reportedly bought shares.
THE APEX TIMES
A new industry study on Italy’s data center market for the 2026-2031 period frames investment and growth opportunities and lists major cloud and infrastructure providers, including Oracle.
THE APEX TIMES
A Yahoo Finance report says Moderna and Takeda are trying again for FDA approval this summer, while Capricor is working to turn its position in a new sleep treatment into a commercial foothold.
THE APEX TIMES
A Zacks analyst blog distributed via Yahoo Finance grouped Boeing with other widely followed companies, reflecting how market strategists are weighing growth narratives against execution and valuation concerns across the defense and technology ecosystems.
THE APEX TIMES
A report highlighted that two weight-loss drugs now account for nearly two-thirds of Eli Lilly’s revenue, underscoring how much investor expectations are tied to demand for GLP-1-style therapies.
